Madrigal continues to report positive results from its own clinical trials, including the trial.
: Analysts at Piper Sandler recently raised their price target for Madrigal to $400 (up from $336), viewing the competitor data as validation for the entire MASH treatment market rather than a threat. MadrigalŠĀ Dip
The consensus among firms like TipRanks is that Madrigalās treatment could become a "blockbuster," supported by its first-mover advantage in the space. Madrigal continues to report positive results from its
: Evercore ISI explicitly labeled the dip as a Buying Opportunity , maintaining an "Outperform" rating with a price target of $392 . MadrigalŠĀ Dip